Bidi products of company banned by FDA

The products do not meet regulatory standards and hence can no more be sold, distributed or imported in the US

Image
Press Trust of India Washington
Last Updated : Feb 22 2014 | 11:47 AM IST
US regulators today banned the sale and import of a company's "bidi" products as they did not meet regulatory standards.

The US Food and Drug Administration in a statement said the products manufactured by Jash International - Sutra Bidis Red, Sutra Bidis Menthol, Sutra Bidis Red Cone and Sutra Bidis Menthol Cone - were found to be not substantially equivalent to tobacco products commercially marketed.

This means they can no longer be sold or distributed in interstate commerce or imported into the United States.

Also Read

The action marks the first time the FDA has used its authority under the Family Smoking Prevention and Tobacco Control Act to order a manufacturer of currently available tobacco products to stop selling and distributing them.

"Historically, tobacco companies controlled which products came on and off the market without any oversight. But the Tobacco Control Act gave the FDA, a science-based regulatory agency, the authority to review applications and determine which new tobacco products may be sold and distributed under the law in order to protect public health," said Mitch Zeller, director of the FDA's Center for Tobacco Products.

"Companies have an obligation to comply with the law - in this case, by providing evidence to support an SE application," Zeller said.

"Because the company failed to meet the requirement of the Tobacco Control Act, the FDA's decision means that, regardless of when the products were manufactured, these four products can no longer be legally imported or sold or distributed through interstate commerce in the United States," the FDA official said.

FDA said existing inventory may be subject to enforcement action, including seizure, without further notice.

Companies that continue to sell and distribute these products in the United States may be subject to enforcement actions by the FDA, it said.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 22 2014 | 2:15 AM IST

Next Story